The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L03 | Immunostimulants | |
| 3 | L03A | Immunostimulants | |
| 4 | L03AX | Other immunostimulants | |
| 5 | L03AX15 | Mifamurtide |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 0.7 mg |
| Active Ingredient | Description | |
|---|---|---|
| Mifamurtide |
Mifamurtide (MTP-PE) is a fully synthetic derivative of muramyl dipeptide (MDP). MTP-PE is a potent activator of monocytes and macrophages. The exact mechanism by which mifamurtide activation of monocytes and macrophages leads to anti-tumour activity in animals and humans is not yet known. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| MEPACT Powder for concentrate for dispersion for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
